$334 Million is the total value of Opaleye Management Inc.'s 41 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was 32.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| HROW | HARROW HEALTH INC | $79,879,000 | +43.4% | 3,775,000 | 0.0% | 23.92% | +23.5% | |
| OCUL | Buy | OCULAR THERAPEUTIX INC | $32,178,093 | +88.5% | 6,105,900 | +0.5% | 9.64% | +62.4% |
| TELA | TELA BIO INC | $22,054,730 | -7.5% | 2,072,813 | 0.0% | 6.61% | -20.3% | |
| RYTM | RHYTHM PHARMACEUTICALS INC | $13,112,400 | -38.7% | 735,000 | 0.0% | 3.93% | -47.2% | |
| CRNX | Buy | CRINETICS PHARMACEUTICALS INC | $12,622,742 | -5.8% | 785,794 | +7.3% | 3.78% | -18.8% |
| KPTI | Buy | KARYOPHARM THERAPEUTICS INC | $10,934,012 | +155.3% | 2,810,800 | +132.9% | 3.28% | +119.9% |
| KROS | KEROS THERAPEUTICS INC | $10,162,600 | -11.1% | 238,000 | 0.0% | 3.04% | -23.4% | |
| TCON | Buy | TRACON PHARMACEUTICALS INC | $9,004,920 | +31.7% | 4,764,508 | +3.8% | 2.70% | +13.4% |
| ETON | Buy | ETON PHARMACEUTICALS INC | $8,412,250 | +37.5% | 2,185,000 | +0.7% | 2.52% | +18.4% |
| TARA | PROTARA THERAPEUTICS INC | $8,077,883 | +11.9% | 2,692,594 | 0.0% | 2.42% | -3.6% | |
| BIOHAVEN LTD | $7,376,400 | -1.6% | 540,000 | 0.0% | 2.21% | -15.2% | ||
| CYTK | Sell | CYTOKINETICS INC | $7,301,925 | -36.3% | 207,500 | -17.0% | 2.19% | -45.1% |
| KALV | KALVISTA PHARMACEUTICALS INC | $7,256,352 | +16.3% | 923,200 | 0.0% | 2.17% | +0.1% | |
| PCVX | VAXCYTE INC | $6,633,960 | -21.8% | 177,000 | 0.0% | 1.99% | -32.7% | |
| LRMR | Sell | LARIMAR THERAPEUTICS INC | $6,346,530 | -1.5% | 1,401,000 | -10.2% | 1.90% | -15.1% |
| TBPH | Buy | THERAVANCE BIOPHARMA INC | $5,927,398 | +503.1% | 546,304 | +523.6% | 1.78% | +419.0% |
| ARQT | New | ARCUTIS BIOTHERAPEUTICS INC | $5,522,000 | – | 502,000 | +100.0% | 1.65% | – |
| FDMT | Sell | 4D MOLECULAR THERAPEUTICS INC | $5,397,660 | -26.4% | 314,000 | -4.8% | 1.62% | -36.6% |
| JNCE | New | JOUNCE THERAPEUTICS INC | $5,328,000 | – | 2,880,000 | +100.0% | 1.60% | – |
| Sell | MARINUS PHARMACEUTICALS INC | $5,278,500 | +60.5% | 765,000 | -7.4% | 1.58% | +38.3% | |
| XOMA | XOMA CORP DEL | $5,129,730 | +14.7% | 243,000 | 0.0% | 1.54% | -1.2% | |
| EWTX | Buy | EDGEWISE THERAPEUTICS INC | $5,002,500 | -8.5% | 750,000 | +22.7% | 1.50% | -21.2% |
| MOR | Buy | MORPHOSYS AGsponsored ads | $4,728,240 | +47.3% | 1,194,000 | +33.2% | 1.42% | +26.9% |
| IDYA | Buy | IDEAYA BIOSCIENCES INC | $4,709,390 | +86.7% | 343,000 | +147.1% | 1.41% | +60.9% |
| URGN | Buy | UROGEN PHARMA LTD | $4,666,200 | +7.7% | 505,000 | +3.3% | 1.40% | -7.2% |
| Sell | THESEUS PHARMACEUTICALS INC | $4,334,328 | +62.7% | 488,100 | -8.8% | 1.30% | +40.2% | |
| EDAP | Buy | EDAP TMS S Asponsored adr | $4,233,168 | +29.5% | 382,400 | +24.7% | 1.27% | +11.5% |
| Buy | ASTRIA THERAPEUTICS INC | $4,096,400 | +5.1% | 302,000 | +15.4% | 1.23% | -9.4% | |
| LQDA | Buy | LIQUIDIA CORPORATION | $3,974,632 | +11.4% | 575,200 | +2.7% | 1.19% | -4.0% |
| FBIO | Buy | FORTRESS BIOTECH INC | $3,750,352 | +179.3% | 4,573,600 | +123.1% | 1.12% | +140.5% |
| PHAT | Buy | PHATHOM PHARMACEUTICALS INC | $3,541,440 | -24.4% | 496,000 | +18.8% | 1.06% | -34.9% |
| CDXS | Sell | CODEXIS INC | $3,105,000 | -30.4% | 750,000 | -21.7% | 0.93% | -40.1% |
| IOVA | New | IOVANCE BIOTHERAPEUTICS INC | $2,572,310 | – | 421,000 | +100.0% | 0.77% | – |
| RLAY | New | RELAY THERAPEUTICS INC | $2,066,985 | – | 125,500 | +100.0% | 0.62% | – |
| KZR | New | KEZAR LIFE SCIENCES INC | $1,956,250 | – | 625,000 | +100.0% | 0.59% | – |
| New | MINERALYS THERAPEUTICS INC | $1,800,900 | – | 115,000 | +100.0% | 0.54% | – | |
| STXS | Sell | STEREOTAXIS INC | $1,768,884 | -27.9% | 867,100 | -26.8% | 0.53% | -37.9% |
| TRVI | Buy | TREVI THERAPEUTICS INC | $1,546,230 | +65.2% | 835,800 | +72.3% | 0.46% | +42.0% |
| PRQR | Sell | PROQR THERAPEUTICS NV | $1,390,890 | -74.3% | 653,000 | -55.3% | 0.42% | -77.8% |
| New | NYXOAH S A | $430,159 | – | 57,585 | +100.0% | 0.13% | – | |
| Sell | MODULAR MEDICAL INC | $266,075 | -45.7% | 183,500 | -25.1% | 0.08% | -52.9% | |
| ALLK | Exit | ALLAKOS INC | $0 | – | -153,500 | -100.0% | -0.45% | – |
| BCAB | Exit | BIOATLA INC | $0 | – | -261,800 | -100.0% | -0.75% | – |
| FENC | Exit | FENNEC PHARMACEUTICALS INC | $0 | – | -272,200 | -100.0% | -0.91% | – |
| MRSN | Exit | MERSANA THERAPEUTICS INC | $0 | – | -460,000 | -100.0% | -0.94% | – |
| Exit | AADI BIOSCIENCE INC | $0 | – | -252,046 | -100.0% | -1.12% | – | |
| ZNTL | Exit | ZENTALIS PHARMACEUTICALS INC | $0 | – | -167,500 | -100.0% | -1.17% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CODEXIS INC | 39 | Q3 2023 | 10.9% |
| CHIMERIX INC | 31 | Q3 2022 | 16.4% |
| XOMA CORP DEL | 27 | Q3 2023 | 3.6% |
| FIBROGEN INC | 26 | Q1 2021 | 6.8% |
| BIOLINERX LTD (Does not reflect a reverse stock split effectuated after June 30, 2019) | 26 | Q1 2020 | 2.4% |
| OCULAR THERAPEUTIX INC | 24 | Q3 2023 | 17.6% |
| AXOGEN INC | 20 | Q4 2019 | 18.7% |
| ETON PHARMACEUTICALS INC | 20 | Q3 2023 | 5.6% |
| AMARIN CORP PLC | 20 | Q4 2020 | 6.6% |
| IMPRIMIS PHARMACEUTICALS INC | 19 | Q1 2020 | 5.9% |
View Opaleye Management Inc.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| CHIMERIX INCSold out | February 13, 2023 | 0 | 0.0% |
| Larimar Therapeutics, Inc. | January 23, 2023 | 1,560,000 | 3.6% |
| TELA Bio, Inc. | June 10, 2022 | 1,557,500 | 10.7% |
| Gemini Therapeutics, Inc. /DESold out | February 01, 2022 | 0 | 0.0% |
| Adamas Pharmaceuticals IncSold out | January 26, 2022 | 0 | 0.0% |
| AVENUE THERAPEUTICS, INC. | February 12, 2021 | 9 | 11.0% |
| Cardiff Oncology, Inc. | February 12, 2021 | 9 | 11.0% |
| EDAP TMS SA | February 12, 2021 | 9 | 11.0% |
| Fortress Biotech, Inc. | February 12, 2021 | 9 | 11.0% |
| Gemini Therapeutics, Inc. /DE | February 12, 2021 | 9 | 11.0% |
View Opaleye Management Inc.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-25 |
| 4 | 2024-04-24 |
| 4 | 2024-04-19 |
| SC 13G/A | 2024-04-09 |
| SC 13G | 2024-04-08 |
| 4 | 2024-03-28 |
| 4 | 2024-03-22 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Opaleye Management Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.